My mistake, I would still doubt if more than 1 or 2 survived 5 years, but we'll see when we get the data, I still wouldn't be surprised if all passed on before they could cross-over or were too ill to do so.
As I remember hearing about the last 100+ to enter the trial after the halt, no control patients were permitted because the German's, who were participating in the trial, indicated it would be wrong. I believe the benefits were clearly being seen by them, and those benefits shouldn't be denied anyone. After their insistence, others went along. I suspect if they were really truthful they could have ended the trial early, but the regulator rarely admit it should be done.
Part of my leukemia treatment used Gleevec. It's one of the few drugs that were approved very early in a Phase 3 Trial many years ago. I admired the drug as being perfect for the developer as it held the cancer in check as long as you kept taking it. There are now 3 different generations of the drug, each have different side effects. I did go back to Gleevec at one point, I'd forgotten how bad the muscle cramps I got when on it for sustained periods were, when they reoccurred, I went back on the 3rd generation drug and tolerate it's side effects.
Gary
News 
Market Data 
Discover 
